New findings from a post-hoc analysis of cenobamate use in adults with uncontrolled focal seizures show high rates of seizure reduction, researchers have reported.
Dr Michael Sperling from Thomas Jefferson University, in Philadelphia, Pennsylvania, USA, presented post-hoc long-term efficacy data from US study sites that took part in the C021 global phase 3 trial of cenobamate, treating at least 11 patients at each site.